Key terms
About ENTA
Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases. The firm also conducts research in human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19). The company was founded by Peter O. Kliem Martin Karplus, James Hogle, Gerard Wagner, Peter M. Howley, and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ENTA news
Mar 12
4:13pm ET
Enanta Pharmaceuticals Shareholders Affirm Management Direction
Feb 09
8:09am ET
Enanta price target lowered to $17 from $21 at Oppenheimer
Feb 09
7:58am ET
Oppenheimer Keeps Their Hold Rating on Enanta Pharmaceuticals (ENTA)
Feb 09
12:51am ET
Maintaining Hold on Enanta Pharmaceuticals Amid Near-Term Challenges and Pipeline Potential
Feb 08
8:10am ET
Analysts Offer Insights on Healthcare Companies: Enanta Pharmaceuticals (ENTA) and Arrowhead Pharmaceuticals (ARWR)
Feb 08
6:44am ET
Enanta price target lowered to $26 from $40 at Baird
Feb 08
12:30am ET
Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL), Enanta Pharmaceuticals (ENTA) and Steris (STE)
Feb 07
4:06pm ET
Enanta reports Q1 EPS ($1.58), consensus ($1.22)
Jan 09
1:21am ET
Analysts Are Bullish on These Healthcare Stocks: Enanta Pharmaceuticals (ENTA), Spruce Biosciences (SPRB)
Jan 09
1:01am ET
Analysts Offer Insights on Healthcare Companies: Fusion Pharmaceuticals (FUSN), Enanta Pharmaceuticals (ENTA) and Synlogic (SYBX)
Jan 05
6:30am ET
Analysts Are Bullish on These Healthcare Stocks: Black Diamond Therapeutics (BDTX), Enanta Pharmaceuticals (ENTA)
Jan 04
2:35pm ET
Buy Rating on Enanta Pharmaceuticals Amidst Promising RSV Program Developments and Strategic Expansion into CSU Market
No recent news articles are available for ENTA
No recent press releases are available for ENTA
ENTA Financials
Key terms
Ad Feedback
ENTA Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ENTA Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range